BMC Medicine (May 2023)

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

  • Jin Li,
  • Shukui Qin,
  • Lu Wen,
  • Junsheng Wang,
  • Wenying Deng,
  • Weijian Guo,
  • Tongfu Jia,
  • Da Jiang,
  • Guifang Zhang,
  • Yifu He,
  • Yi Ba,
  • Haijun Zhong,
  • Lin Wang,
  • Xiaoyan Lin,
  • Jianwei Yang,
  • Jun Zhao,
  • Yuxian Bai,
  • Xiangyuan Wu,
  • Feng Gao,
  • Guogui Sun,
  • Yongjuan Wu,
  • Feng Ye,
  • Qiong Wang,
  • Zhong Xie,
  • Tienan Yi,
  • Yong Huang,
  • Guohua Yu,
  • Lin Lu,
  • Ying Yuan,
  • Wei Li,
  • Likun Liu,
  • Yuping Sun,
  • Ying Sun,
  • Lifeng Yin,
  • Zhiguo Hou

DOI
https://doi.org/10.1186/s12916-023-02841-7
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Apatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as a third- and later-line treatment for advanced gastric cancer in phase 2 and 3 trials. This prospective, single-arm, multicenter phase IV AHEAD study was conducted to verify the safety and efficacy of apatinib in patients with advanced or metastatic gastric or gastroesophageal adenocarcinoma after at least two lines of systematic therapy in clinical practice settings. Methods Patients with advanced gastric cancer who had previously failed at least two lines of chemotherapy received oral apatinib until disease progression, death or unacceptable toxicity. The primary endpoint was safety. The secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). Adverse events were summarized by the incidence rate. Median OS and PFS were estimated using the Kaplan–Meier method. ORR, DCR, OS at 3 and 6 months, and PFS at 3 and 6 months were calculated, and their 95% CIs were estimated according to the Clopper-Pearson method. Results Between May 2015 and November 2019, a total of 2004 patients were enrolled, and 1999 patients who received at least one dose of apatinib were assessed for safety. In the safety population, 87.9% of patients experienced treatment-related adverse events (TRAEs), with the most common hypertension (45.2%), proteinuria (26.5%), and white blood cell count decreased (25.3%). Additionally, 51% of patients experienced grade ≥ 3 TRAEs. Fatal TRAEs occurred in 57 (2.9%) patients. No new safety concerns were reported. Among the 2004 patients included in the intention-to-treat population, the ORR was 4.4% (95% CI, 3.6–5.4%), and DCR was 35.8% (95% CI, 33.7–38.0%). The median PFS was 2.7 months (95% CI 2.2–2.8), and the median OS was 5.8 months (95% CI 5.4–6.1). Conclusions The findings in the AHEAD study confirmed the acceptable and manageable safety profile and clinical benefit of apatinib in patients with advanced gastric cancer as a third- or later-line of treatment. Trial registration This study was registered with ClinicalTrials.gov NCT02426034. Registration date was April 24, 2015.

Keywords